Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 689-723

  Shitara, Yoshihisa ^a   Sato, Hitoshi ^a   Sugiyama, Yuichi ^b  

^a SHOWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Pharmacokinetics; Quantitative prediction of drug drug interaction; Transporter

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIBIOTIC AGENT; ATORVASTATIN; CEFACLOR; CEFALEXIN; CEFAZOLIN; CEFMETAZOLE; CEFOXITIN; CEFRADINE; CEPHALOSPORIN DERIVATIVE; CERIVASTATIN; CYCLOSPORIN A; DIGOXIN; FLUINDOSTATIN; GEMFIBROZIL; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER; PEPTIDE TRANSPORTER 1; PITAVASTATIN; PRAVASTATIN; PROBENECID; QUINIDINE; QUININE; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG;

BILIARY EXCRETION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; GENE EXPRESSION; HEPATOBILIARY SYSTEM; HUMAN; KIDNEY METABOLISM; KIDNEY SLICE; LIVER CELL CULTURE; LIVER METABOLISM; LIVER SLICE; MEMBRANE VESICLE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REVIEW;

ANIMALS; BILIARY TRACT; BIOLOGICAL TRANSPORT; DRUG EVALUATION; DRUG INTERACTIONS; HUMANS; KIDNEY; LIVER; PHARMACEUTICAL PREPARATIONS;

AVENA; CINCHONA PUBESCENS;

EID: 13844314148     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.44.101802.121444     Document Type: Review

References (200)

1. Petzinger E. 1994. Transport of organic anions in the liver. An update on bile acid, fatty acid, monocarboxylate, anionic amino acid, cholephilic organic anion, and anionic drug transport. Rev. Physiol. Biochem. Pharmacol. 123:47-211
2. Oude Elferink RPJ, Meijer DKF, Kuipers F, Jansen PLM, Groen AK, Groothis GMM. 1995. Hepatobiliary secretion of organic compounds; molecular mechanism of membrane transport. Biochem. Biophys. Acta 1241:215-68
3. Yamazaki M, Suzuki H, Sugiyama Y. 1996. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 13:497-513
4. Okudaira N, Sugiyama Y. 1996. Use of an isolated perfused kidney to assess renal clearance of drugs: information obtained in steady-state and non-steady-state experimental systems. In Models for Assessing Drug Absorption and Metabolism, ed RT Borchard, PL Smith, G Wilson, pp. 211-38. New York: Plenum Press
5. Giacomini KM, Hsyu PH, Gisclon JG. 1988. Renal transport of drugs: an overview of methodology with application to cimetidine. Pharm. Res. 5:465-71
6. van Aubel RAMH, Masereeuw R, Russel FGM. 2000. Molecular pharmacology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. 279:F216-32
7. Kusuhara H, Sugiyama Y. 2002. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control. Release 78:43-54
8. Kusuhara H, Suzuki H, Sugiyama Y. 1998. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. 87:1025-40
9. Suzuki H, Sugiyama Y. 2000. Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. Semin. Liver Dis. 20:251-63
10. Inui K, Masuda S, Saito H. 2000. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 58:944-58
11. Dresser MJ, Leabman MK, Giacomini KM. 2001. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. 90:397-421
12. Sweet DH, Bush KT, Nigam SK. 2001. The organic anion transporter family: from physiology to ontogeny and the clinic. Am. J. Physiol. Renal Physiol. 281: F197-205
13. Sekine T, Cha SH, Endou H. 2000. The multispecific organic anion transporter (OAT) family. Pflugers Arch. 440:337-50
14. Koepsell H, Gorboulev V, Arndt P. 1999. Molecular pharmacology of organic cation transporters in the kidney. J. Membr. Biol. 167:103-17
15. Mizuno N, Sugiyama Y. 2002. Drugtransporters: their roles and importance in the selection and development of new drugs. Drug Metab. Pharmacokin. 17:93-108
16. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. 1997. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667-77
17. Pang KS, Rowland M. 1977. Hepatic clearance of drugs I: theoretical considerations of a "well-stirred" model and a "parallel- tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokin. Biopharm. 5:625-53
18. Pang KS, Gillette R. 1978. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: difference between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin. J. Pharmacol. Exp. Ther. 207:178-94
19. Miyauchi S, Sugiyama Y, Sawada Y, Morita K, Iga T, et al. 1987. Kinetics of hepatic transport of 4-methylumbel-liferone in rats: analysis by multiple indicator dilution method. J. Pharmacokin. Biopharm. 15:25-38
20. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. 1997. Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 272:18526-29
21. Hosoyamada M, Sekine T, Kanai Y, Endou H. 1999. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. Renal Physiol. 276:F122-28
22. Sun W, Wu RR, van Poelje PD, Erion MD. 2001. Isolation of a family of organic anion transporters from human liver and kidney. Biochem. Biophys. Res. Comm. 283:417-22
23. Race JE, Grassl SM, Williams WJ, Holtzman EJ. 1999. Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem. Biophys. Res. Commun. 255:508-14
24. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, et al. 2000. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem. 275:4507-12
25. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, et al. 2001. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59:1277-86
26. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, et al. 2002. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 302:666-71
27. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, et al. 2002. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 300:918-24
28. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, et al. 2001. Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 69:2123-35
29. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, et al. 2000. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol. Pharmacol. 57:24-35
30. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, et al. 2001. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 296:723-35
31. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, et al. 1992. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. USA 89:8472-76
32. Adachi Y, Suzuki H, Sugiyama Y. 2001. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 18:1660-68
33. Guo A, Marinaro W, Hu P, Sinko PJ. 2002. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Dispos. 30:457-63
34. Walle UK, Walle T. 1998. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab. Dispos. 26:343-46
35. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, et al. 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263:840-45
36. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, et al. 1992. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol Chem. 267:24248-52
37. Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH. 1995. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J. Biol. Chem. 270:25672-77
38. Smith DE, Pavlova A, Berger UV, Hediger MA, Yang T, et al. 1998. Tubular localization and tissue distribution of peptide transporters in rat kidney. Pharm. Res. 15:1244-49
39. Shen H, Smith DE, Yang T, Huang YG, Schnermann JB, et al. 1999. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am. J. Physiol. Renal Physiol. 276:F658-65
40. Tsuji A. 2002. Transporter-mediated drug interactions. Drug. Metabol. Pharmacokin. 17:253-74
41. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, et al. 1999. CHO/hPEPT1 cells over-expressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J. Pharm. Sci. 88:347-50
42. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, et al. 1997. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell. Biol. 16:871-81
43. Zhang L, Schaner ME, Giacomini KM. 1998. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J. Pharmacol. Exp. Ther. 286:354-61
44. Dudley AJ, Bleasby K, Brown CD. 2000. The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK1 cell monolayers. Br. J. Pharmacol. 131:71-79
45. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, et al. 1998. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. 54:342-52
46. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K. 2002. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 13:1703-10
47. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, et al. 1997. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett. 419:107-11
48. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, et al. 1999. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 289:768-73
49. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, et al. 1998. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem. 273:20378-82
50. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, et al. 1999. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol. Exp. Ther. 290:1482-92
51. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, et al. 1999. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat. Genet 21:91-94
52. +-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther. 291:778-84
53. Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, et al. 2000. β-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J. Biol. Chem. 275:1699-707
54. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, et al. 2000. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273:251-60
55. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, et al. 1999. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274:37161-68
56. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, et al. 2001. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. 297:861-67
57. König J, Cui Y, Nies AT, Keppler D. 2000. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278:G156-64
58. König J, Cui Y, Nies AT, Keppler D. 2000. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 275:23161-68
59. +-independent organic anion transporter. Proc. Natl. Acad. Sci. USA. 91:133-37
60. Noé B, Hagenbuch B, Stieger B, Meier PJ. 1997. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. USA 94:10346-50
61. Carton V, Hagenbuch B, Hagenbuch N, Stieger B, Ha R, et al. 2000. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. FEBS Lett. 474:242-45
62. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. 2003. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 304:610-16
63. Pang KS, Wang PJ, Chung AYK, Wolkoff AW. 1998. The modified dipeptide enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology 28:1341-46
64. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, et al. 1998. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J. Pharmacol. Exp. Ther. 287:37-42
65. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, et al. 2001. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-33
66. Jansen PL, Peters WH, Lamers WH. 1985. Hereditary chronic conjugated hyperbilirunemia in mutant rats caused by defective hepatic anion transport. Hepatology 5:573-79
67. Hosokawa S, Tagaya O, Mikami T, Nozaki Y, Kawaguchi Y, et al. 1992. A new rat mutant with chronic conjugated hyperbilirunemia and renal glomerular lesions. Lab. Animal Sci. 42:27-34
68. Muller M, Jansen PL. 1997. Molecular aspects of hepatobiliary transport. Am. J. Physiol. Gastrointest. Liver Physiol. 272:01285-303
69. Oude Elferink RP, Meijer DK, Kuipers F, Jansen PL, Groen AK, et al. 1995. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1241:215-68
70. Stieger B, Meier PJ. 1998. Bile acid and xenobiotic transporters in liver. Curr. Opin. Cell. Biol. 10:462-67
71. Suzuki H, Sugiyama Y. 1998. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin. Liver Dis. 18:359-76
72. König J, Nies AT, Cui Y, Leier I, Keppler D. 1999. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461:377-94
73. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, et al. 1996. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126-28
74. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, et al. 1997. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am. J. Physiol. Gastrointest. Liver Physiol. 272:G16-22
75. Buchler M, König J, Brom M, Kartenbeck J, Spring H, et al. 1996. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271:15091-98
76. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56:4124-29
77. Borst P, Evers R, Kool M, Wijnholds J. 1999. The multidrug resistance protein family. Biochim. Biophys. Acta 1461:347-57
78. Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, Wada M. 1999. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des. 14:123-31
79. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, et al. 1997. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem. J. 327:305-10
80. Niinuma K, Kalo Y, Suzuki H, Tyson CA, Weizer V, et al. 1999. Primary active transport of organic anions on bile canalicular membrane in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 276:G1153-64
81. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, et al. 1999. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55:929-37
82. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, et al. 1999. Primary active transport of organic anions on bile canalicular membrane in humans. Am. J. Physiol. Gastmintest. Liver Physiol. 276:01153-64
83. Paulusma CC, van Geer MA, Evers R, Heijn M, Ottenhoff R, et al. 1999. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem. J. 338:393-401
84. Ryu S, Kawabe T, Nada S, Yamaguchi A. 2000. Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J. Biol. Chem. 275:39617-24
85. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. 2002. Transcellular transport of organic aidons across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem. 277:6497-503
86. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, et al. 1999. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:2532-35
87. Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm. Res. 19:773-79
88. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, et al. 1999. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 56:1219-28
89. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y. 2002. Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm. Res. 19:34-41
90. Zeng H, Liu G, Rea PA, Kruh GD. 2000. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 60:4779-84
91. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95:15665-70
92. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. 1998. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58:5337-39
93. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, et al. 1999. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells. Cancer Res. 59:8-13
94. Maliepaard M, Scheffer GL, Faneyte BF, van Gastelen MA, Pijnenborg ACLM, et al. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:3458-64
95. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. 2003. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. 278:22644-49
96. Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, et al. 1999. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett. 461:339-42
97. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, et al. 2002. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J. Pharmacol. Exp. Ther. 300:746-53
98. Hori R, Ishikawa Y, Takano M, Okano T, Kitazawa S, et al. 1982. The interaction of cephalosporin antibiotics with renal cortex of rats: accumulation to cortical slices and binding to purified plasma membranes. Biochem. Pharmacol. 31:2267-72
99. Terada T, Sawada K, Ito T, Saito H, Hashimoto Y, et al. 2000. Functional expression of novel peptide transporter in renal basolateral membranes. Am. J. Physiol. Renal Physiol. 279:F851-57
100. Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, et al. 1999. Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. J. Pharmacol. Exp. Ther. 290:1107-15
101. Ishigami M, Tokui T, Komai T, Tsukahara K, Yamazaki M, et al. 1995. Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Pharm. Res. 12:1741-45
102. Madan A, DeHaan R, Mudra D, Carroll K, LeCluyse E, Parkinson A. 1999. Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metab. Dispos. 27:327-35
103. Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. 1997. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interact. 107:5-16
104. Li AP, Lu C, Brent JA, Pham C, Fackett A, et al. 1999. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121:17-35
105. Li AP, Gorycki PD, Hengstler JG, Kedderis GL, Koebe HG, et al. 1999. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem. Biol. Interact. 121:117-23
106. Shitara Y, Li AP, Kato Y, Lu C, Ito K, et al. 2003. Function of uptake transporters for taurocholate and estradiol 17β- D-glucuronide in cryopreserved human hepatocytes. Drug Metab. Pharmacokin. 18:33-41
107. Olinga P, Hof IH, Merema MT, Smit M, de Jager MH, et al. 2001. The applicability of rat and human liver slices to the study of mechanisms of hepatic drug uptake. J. Pharmacol. Toxicol. Methods 45:55-63
108. Shigematsu A, Motoji N, Momose Y, Iida A, Higashi N. 2000. Viability of liver slices exhibiting absorption, metabolism, and elimination of substrates in culture medium. Exp. Mol. Pathol. 69:119-43
109. Pritchard JB, Miller DS. 1993. Mechanisms mediating renal secretion of organic anions and cations. Physiol. Rev. 73:765-96
110. Murer H, Gmaj P, Steiger B, Hagenbuch B. 1989. Transport studies with renal proximal tubular and small intestinal brush border and basolateral membrane vesicles: vesicle heterogeneity, coexistence of transport system. Methods Enzymol. 172:346-64
111. Boyer JL, Meier PJ. 1990. Characterizing mechanisms of hepatic bile acid transport utilizing isolated membrane vesicles. Methods Enzymol. 192:517-33
112. Kinne-Saffran E, Kinne RK. Isolation of luminal and cotralumenal plasma membrane vesicles from kidney. Methods Enzymol. 191:450-69
113. Meier PJ, Boyer JL. 1990. Preparation of basolateral (sinusoidal) and canalicular plasma membrane vesicles for the study of hepatic transport processes. Methods Enzymol. 192:534-45
114. Meier PJ, St Meier-Abt A, Barrett C, Boyer JL. 1984. Mechanisms of taurocholate transport in canalicular and basolateral rat liver plasma membrane vesicles. Evidence for an electrogenic canalicular organic anion carrier. J. Biol. Chem. 259:10614-22
115. Cui Y, Konig J, Keppler D. 2001. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol. 60:934-43
116. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, et al. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94:4028-33
117. Hagenbuch B, Scharschmidt BF, Meier PJ. 1996. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem. J. 316:901-4
118. Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, et al. 1997. The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J. Pharm. Pharmacol. 49:796-801
119. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. 1998. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J. Pharmacol. Exp. Ther. 286:1043-50
120. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. 1999. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J. Pharmacol. Exp. Ther. 288:627-34
121. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311:139-46
122. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T. 2002. Comparative inhibitory effects of different compounds on rat oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm. Res. 19:147-53
123. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, et al. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 50:387-412
124. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. 1998. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38:461-99
125. Ueda K, Kato Y, Komatsu K, Sugiyama Y. 2001. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J. Pharmacol. Exp. Ther. 297:1036-43
126. Saito H, Masuda S, Inui K. 1996. Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J. Biol. Chem. 271:20719-25
127. Masuda S, Saito H, Inui K. 1997. Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1. J. Pharmacol. Exp. Ther. 283:1039-42
128. Masuda S, Takeuchi A, Saito H, Hashimoto Y, Inui K. 1999. Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane. FEBS Lett. 459:128-32
129. Masuda S, Ibaramoto K, Takeuchi A, Saito H, Hashimoto Y, et al. 1999. Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney. Mol. Pharmacol. 55:743-52
130. Takeuchi A, Masuda S, Saito H, Abe T, Inui K. 2001. Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2. J. Pharmacol. Exp. Ther. 299:261-67
131. Lu R, Kanai N, Bao Y, Wolkoff AW, Schuster VL. 1996. Regulation of renal oatp mRNA expression by testosterone. Am. J. Physiol. Renal Physiol. 270:F332-37
132. Yamazaki M, Tokui T, Ishigami M, Sugiyama Y. 1996. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. Biopharm. Drug Dispos. 17:775-89
133. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson B. 1990. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin. Pharmacol. Ther. 47:20-26
134. Bohme M, Jedlitschky G, Leier I, Buchler M, Keppler D. 1994. ATP-dependent export pumps and their inhibition by cyclosporins. Adv. Enzyme Regul. 34:371-80
135. Versantvoort CH, Broxterman HJ, Lankelma J, Feller N, Pinedo HM. 1994. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol 48:1129-36
136. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, et al. 1997. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther. 281:304-14
137. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, et al. 1993. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 84:697-702
138. Gupta E, Lestingi TM, Mick R, Ramirez J, Yokes EE, et al. 1994. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54:3723-25
139. Horikawa M, Kato Y, Tyson CA, Sugiyama Y. 2002. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the bibiary excretion of irinotecan metabolites. Drug Metab. Pharmacokin. 17:23-33
140. Horikawa M, Kato Y, Sugiyama Y. 2002. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm. Res. 19:1345-53
141. Mück W. 2000. Clinical pharmacokinetics of cerivastatin. Clin. Pharmacokinet. 39:99-116
142. Mück W, Mai I, Pritsche L, Ochmann K, Rohde G, et al. 1999. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporin-treated kidney transplant recipients. Clin. Pharmacol Ther. 65:251-61
143. Regazzi MB, Campana IC, Raddato V, Lesi C, Perani G, et al. 1993. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant. Proc. 25:2732-34
144. Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, et al. 2003. The drug-drug interactions of pitavstatm (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J. Clin. Ther. Med. 19:381-89
145. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. 2001. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am. J. Transplant. 1: 382-86
146. Lennernas H. 2003. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42:1141-60
147. Bruce-Joyce J, Dugas JM, MacCausland OE. 2001. Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann. Pharmacother. 35:1016-19
148. Mueck W, Frey R, Boix O, Voith B. 2001. Gemfibrozil/cerivastatin interaction. AAPS PharmSci. 3(Suppl.):3566 (Abstr.)
149. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. 2002. Gemflbrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72:685-91
150. Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemflbrozil and its glucuronide inhibit the OATP2(OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin-analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311:228-36
151. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, et al. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol Ther. 75:455-63
152. Sallustio BC, Fairchild BA, Shanahan K, Evans AM, Nation RL. 1996. Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab. Dispos. 24:984-89
153. Sabordo L, Sallutio BC, Evans AM, Nation RL, 1998. Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil β-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation. J. Pharmacol. Exp. Ther. 288:414-20
154. Sabordo L, Sallustio BC, Evans AM, Nation RL. 2000. Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-β-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. J. Pharmacol Exp. Ther. 295: 44-50
155. Hedman A, Meijer DK. 1998. Stereoselective inhibition by the diastereomers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes. J. Pharm. Sci. 87:457-61
156. Olinga P, Merema M, Hof IH, Slooff MJ, Proost JH, et al. 1998. Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. J. Pharmacol. Exp. Ther. 285:506-10
157. Brown GR. 1993. Cephalosporin-probenecid drug interactions. Clin. Pharmacokinet. 24:289-300
158. Marino EL, Dominguez-Gil A. 1981. The pharmacokinetics of cefadroxil
159. Griffith RS, Black HR, Brier GL, Wolny JD. 1977. Effect of probenecid on the blood levels and urinary excretion of cefamandole. Antimicrob. Agents Chemother. 11:809-12
160. Stoeckel K, Trueb V, Dubach UC, McNamara PJ. 1988. Effect of probenecid on the elimination and protein binding of ceftriaxone. Eur. J. Clin. Pharmacol. 34:151-56
161. Furst DE. 1995. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br. J. Rheumatol. 34(Suppl. 2):20-25
162. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, et al. 1992. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur. J. Clin. Pharmacol. 42:121-25
163. Kremer JM, Hamilton RA. 1995. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J. Rheumatol. 22:2072-77
164. Frenia ML, Long KS. 1992. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann. Pharmacother. 26:234-37
165. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. 2004. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J. Pharmacol. Exp. Ther. 309: 226-34
166. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, et al. 1999. Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol. Pharmacol. 55:847-54
167. Uwai Y, Saito H, Inui K. 2000. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur. J. Pharmacol. 409:31-36
168. Lu R, Chan BS, Schuster VL. 1999. Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am. J. Physiol. Renal Physiol. 276:F295-303
169. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, et al. 2002. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J. Neurochem. 83:57-66
170. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, et al. 1998. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 429:179-82
171. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y. 2001. Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J. Pharmacol. Exp. Ther. 298:1179-84
172. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, et al. 1999. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J. Biol. Chem. 274:13675-80
173. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, et al. 1999. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J. Pharmacol. Exp. Ther. 290:672-77
174. Takeda M, Babu E, Narikawa S, Endou H. 2002. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur. J. Pharmacol. 438:137-42
175. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, et al. 2002. Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 70:1861-74
176. Uwai Y, Saito H, Inui K. 2002. Rat renal organic anion transporter rOAT1 mediated transport of urinary-excreted cephalosporins, but not of biliary excreted cefoperazone. Drug Metab. Pharmacokin. 17:125-29
177. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, et al. 2002. Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim. Biophys. Acta 1590:64-75
178. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, et al. 2002. Human organic anion transporters mediate the transport of tetracycline. Jpn. J. Pharmacol. 88:69-76
179. Uwai Y, Saito H, Hashimoto Y, Inui K. 2000. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J. Pharmacol Exp. Ther. 295:261-65
180. Uwai Y, Saito H, Hashimoto Y, Inui K. 2000. Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur. J. Pharmacol. 398:193-97
181. Nagata Y, Kusuhara H, Endou H, Sugiyama Y. 2002. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol. Pharmacol. 61:982-88
182. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, et al. 2001. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur. J. Pharmacol. 419:113-20
183. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, et al. 2002. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J. Pharmacol. Exp. Ther. 301:797-802
184. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:866-71
185. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, et al. 1999. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm. Res. 16:904-8
186. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, et al. 1998. Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 424:173-76
187. Bossuyt X, Muller M, Hagenbuch B, Meier PJ. 1996. Poly specific drug and steroid clearance by an organic anion transporter of mammalian liver. J. Pharmacol. Exp. Ther. 276:891-96
188. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, et al. 2001. Characterization of the efflux transport of 17β-estradiol-D-glucuronide from the brain across the blood-brain barrier. J Pharmacol. Exp.
189. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Sugiyama Y. 2002. Effect of 17β-estradiol-D-17β-glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates. Drug Metab. Dispos. 30:220-23
190. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, et al. 2001. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120:1689-99
191. Vavricka SR, van Montfoort J, Ha HR, Meier PJ, Fat tinger K. 2002. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-72
192. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. 2000. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86
193. Ichimaru N, Takahara S, Kokado Y, Wang J-D, Hatori M, et al. 2001. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158:471-23
194. Amadottir M, Eriksson LO, Thysell H, Karkas JD. 1993. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. Nephron 65:410-13
195. Goldberg R, Roth D. 1996. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 62:1559-34
196. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Latila J, et al. 2001. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69:340-45
197. Backman JT, Kyrklund C, Kivistö KT, Wang J-S, Neuvonen PJ. 2000. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68:122-29
198. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 73:538-44
199. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. 1995. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. 76:80A-83
200. Mathew P, Cuddy T, Tracewell WG, Salazar D. 2004. An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin. Pharmacol. Ther. 75:P33